Platform Trials Are Rewriting the Rules of Evidence Generation. Regulators Haven't Caught Up.

Adaptive platform trials are changing how clinical evidence is generated by allowing multiple interventions to be tested simultaneously under a single protocol, improving speed and efficiency. However, regulatory frameworks like those at the FDA have not evolved to address the complexity and risks introduced by these trials, such as control arm biases and multi-site variability.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.